文献速递妇科

中国宫颈癌患者鳞状细胞癌与腺癌免疫特征及基因组图谱差异的多中心研究

The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
PubMed 文献 · Gynecol Oncol · 2023-06-23

该多中心研究纳入2014至2021年中国7家医疗中心336例宫颈癌患者(鳞癌254例 vs 腺癌82例),对肿瘤组织及液体活检行425个癌症相关基因二代测序。腺癌多见STK11改变(P=0.039),鳞癌肿瘤突变负荷更高(P=0.01)、TMB-high比例更高(P=0.016)、PD-L1高表达更多(P=0.0013)。

要点

  • 腺癌STK11改变更多(P=0.039),鳞癌TMB更高(P=0.01)且PD-L1高表达更多(P=0.0013)。
  • 腺癌富集TP53、KRAS、ERBB2、ARID1A改变,鳞癌富集PIK3CA、FBXW7、EP300、BAP1突变。
  • 腺癌富集遗传改变与多种B细胞、T细胞及树突状细胞浸润减少相关,鳞癌相关分子特征倾向与CD4+ T细胞浸润增加相关。

核心结论

  • 本研究首次揭示中国宫颈癌患者鳞癌与腺癌的免疫及基因组特征差异,遗传图谱差异可能提示两种亚型可采用不同治疗方案,鳞癌免疫治疗疗效可能更好,腺癌靶向治疗选择可能更有利。

研究设计与样本

  • 2014至2021年中国7家医疗中心纳入336例宫颈癌患者(鳞癌254例 vs 腺癌82例),对肿瘤组织及液体活检行425个癌症相关基因二代测序,分析体细胞改变及免疫应答相关生物标志物,并利用癌症基因组图谱(TCGA)数据分析患者预后与免疫浸润。

主要发现

  • 腺癌倾向有更多免疫治疗耐药相关STK11改变(P=0.039)、更高微卫星不稳定比例(P=0.21)及更多可靶向突变(P=0.161)。
  • 鳞癌肿瘤突变负荷更高(P=0.01)、TMB-high患者比例更高(P=0.016)、PD-L1高表达患者更多(P=0.0013)。
  • 腺癌特异性富集TP53、KRAS、ERBB2、ARID1A改变,鳞癌特异性富集PIK3CA、FBXW7、EP300、BAP1突变。
  • 腺癌富集遗传改变与多种B细胞、T细胞及树突状细胞浸润减少显著相关,鳞癌相关分子特征倾向与CD4+ T细胞浸润增加相关。

临床怎么用

  • 作者认为遗传图谱差异可能提示两种宫颈癌亚型可采用不同治疗方案,鳞癌免疫治疗疗效可能更好,腺癌靶向治疗选择可能更有利。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the uterine cervix have distinct biological behaviors and different treatment responses. Studies on immune features and genomic profiling of these two pathologic types were limited and mainly focused on small patient cohorts. METHODS: From 2014 to 2021, 336 (254 SCC vs. 82 AC) cervical cancer patients who were diagnosed/treated in 7 medical centers in China were enrolled in the study. Next-generation sequencing of 425 cancer-relevant genes was performed on tumor tissues and liquid biopsies. Somatic alterations and immune response-related biomarkers were analyzed. Patient prognosis and immune infiltration were analyzed using data from The Cancer Genome Atlas (TCGA). RESULTS: AC tended to have more immunotherapy resistance-related STK11 alterations (P = 0.039), a higher proportion of microsatellite instability (P = 0.21), and more actionable mutations (P = 0.161). In contrast, higher tumor mutational burdens (TMB; P = 0.01), a higher proportion of TMB-high patients (P = 0.016), and more PD-L1-high patients (P = 0.0013) were observed in SCC. Multiple genetic alterations and aberrant signaling pathways were specifically enriched in AC (e.g., TP53, KRAS, ERBB2, and ARID1A alterations) or SCC (e.g., PIK3CA, FBXW7, EP300, and BAP1 mutations). Notably, AC-enriched genetic changes were significantly associated with decreased infiltrations of various B cells, T cells, and dendritic cells, whereas SCC-associated molecular features tended to be associated with increased CD4+ T cell infiltrations. CONCLUSIONS: This was the first multi-center study revealing the immunologic and genomic features between SCC and AC in Chinese patients with cervical cancer. Our findings have illustrated the difference in genetic profiles of those two cervical cancer subtypes, which may suggest the possibility of differential treatment regimens, with better immunotherapy efficacy in SCC and targeted therapy options more favorable in AC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Xue X, Zhang Y, et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023. PMID: 37356314. doi:10.1016/j.ygyno.2023.05.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。